Aldesleukin therapy in HIV-infected patients

American Journal of Health-System Pharmacy

Volumn 55, Issue 14, 1998, Pages 1520-1523

  Sundin, David J ^a,b   Wolin, Maurice J ^b  

^a Professional Services Department   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032528097     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.14.1520     Document Type: Review

References (21)

1. Autran B, Carcelain G, Li T et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997; 277:112-6.
2. Connors M, Kovacs J, Krevat S et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997; 3:533-40.
3. Rosenberg S, Grimm E, McGrogan M et al. Biological activity of recombinant interleukin-2 produced in Escherichia coli. Science. 1984; 223:1412-4.
4. Smith K. Interleukin-2: inception, impact and implications. Science. 1988; 240:1169-76.
5. Smith K. Lowest dose interleukin-2 immunotherapy. Blood. 1993; 81:1414-23.
6. Lane HC, Siegel J, Rook A et al. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Mod. 1984; 3:512-6.
7. Mertelsman R, Welte K, Sternberg C et al. Treatment of immunodeficiency with interleukin-2: initial exploration. J Biol Response Mod. 1984; 4:283-90.
8. Volberding P, Moody D, Beardslee D et al. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses. 1987; 3(2):115-24.
9. McMahon D, Armstrong J, Huang X et al. A Phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS. 1994; 8(1):59-66.
10. Schwartz D, Skowron G, Merigan T. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1991; 4(1):11-23.
11. Kovacs J, Baseler M, Dewar R et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med. 1995; 332:567-75.
12. Falloon J, Owen C, Metcalf J et al. Indinavir and interleukin-2 in HIV: one year follow-up. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 15-18.
13. Kovacs J, Vogel S, Albert J et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996; 335:1350-6.
14. Saravolatz L, Mitsuyasu R, Sneller M et al. Duration of Proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 15-18.
15. Davey R, Chaitt D, Piscitelli S et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type-1 infected persons. J Infect Dis. 1997; 175:781-9.
16. Davey R, Chaitt D, Kovacs J et al. Subcutaneous interleukin-2 therapy is capable of inducing marked sustained increases in CD4 counts in early HIV-infected patients. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 6-11.
17. Jacobson E, Pilaro F, Smith K. Rational interleukin-2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A. 1996; 93:10405-10.
18. Kovacs JA, Davey RT, Lane HC. Interleukin-2 infusions in HIV-infected patients. N Engl J Med. 1997; 336:1260-1. Letter.
19. Caliguri M. Low-dose recombinant interleukin-2 therapy: rational and potential clinical applications. Semin Oncol. 1993; 20(suppl 9):3-10.
20. 3. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 6-11.
21. Emery S, Capra W, Vig P et al. IL-2 therapy in HIV disease: a pooled analysis of three randomized, controlled trials. Paper presented at 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; 1998 Feb 1-5.